enVVeno Medical Corporation (NASDAQ:NVNO - Get Free Report) shares fell 1.8% during mid-day trading on Tuesday . The stock traded as low as $4.90 and last traded at $4.91. 45,328 shares were traded during mid-day trading, a decline of 56% from the average session volume of 102,538 shares. The stock had previously closed at $5.00.
enVVeno Medical Stock Down 1.8 %
The company has a market cap of $65.45 million, a price-to-earnings ratio of -2.96 and a beta of 1.10. The stock's 50-day simple moving average is $5.22 and its 200 day simple moving average is $4.84.
enVVeno Medical (NASDAQ:NVNO - Get Free Report) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.31) EPS for the quarter. On average, sell-side analysts expect that enVVeno Medical Corporation will post -1.4 EPS for the current fiscal year.
Insider Activity at enVVeno Medical
In other news, CTO Hamed Alavi sold 8,334 shares of the firm's stock in a transaction that occurred on Wednesday, March 13th. The shares were sold at an average price of $6.22, for a total value of $51,837.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 17.00% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On enVVeno Medical
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Armistice Capital LLC purchased a new position in enVVeno Medical in the fourth quarter worth approximately $2,241,000. Kingdon Capital Management L.L.C. lifted its position in shares of enVVeno Medical by 182.5% during the 4th quarter. Kingdon Capital Management L.L.C. now owns 619,180 shares of the company's stock worth $3,183,000 after purchasing an additional 400,000 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of enVVeno Medical by 70.6% during the first quarter. Vanguard Group Inc. now owns 573,955 shares of the company's stock worth $3,122,000 after purchasing an additional 237,550 shares in the last quarter. RIA Advisory Group LLC purchased a new position in enVVeno Medical in the first quarter valued at $238,000. Finally, Janney Montgomery Scott LLC acquired a new stake in enVVeno Medical in the first quarter valued at $186,000. 34.71% of the stock is owned by institutional investors and hedge funds.
About enVVeno Medical
(
Get Free Report)
enVVeno Medical Corporation Nasdaq: NVNO is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider enVVeno Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and enVVeno Medical wasn't on the list.
While enVVeno Medical currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
